4D Molecular Corp (FDMT) - רווח נקי למניה (EPS TTM)

The price action reflects a current EPS of 28.80. 4D Molecular Therapeutics specializes in developing precision viral capsids for the targeted delivery of genetic code to heart and eye tissues. The business relies on an advanced IT platform for DNA vector maturation, while stable management with a deep scientific background strictly controls the timelines for all R&D projects.
4D Molecular Therapeutics - פילוחים אנליטיים ומדדי מפתח (FDMT)

Minimizing fundamental risks requires an analysis of the rate of change in earnings per share. For 4D Molecular Therapeutics (FDMT), this process depends directly on the success of gene therapy clinical trials and the efficiency of biomanufacturing. The history of EPS YoY (TTM) percentage changes reflects the rolling annual growth dynamics, measuring the speed of capital scaling. Positive momentum in this metric confirms the issuer's market adaptability and the potential for share price growth.